L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
Immunophenotypic and genetic characterization of a CD8 positive Mantle Cell Lymphoma in a patient with concomitant Mycosis Fungoides
Roland Schroers,York Hildebrandt,Rainer Steffens,Sabrina Becker,Gudrun Ohms,Frederike von Bonin,Detlef Haase,Hans Peter Bertsch,Lorenz Trümper,Frank Griesinger +9 more
TL;DR: The first case of a blastic MCL in leukaemic phase with aberrant expression of the T‐cell associated antigen CD8 occurring in a patient with concomitant Mycosis fungoides is described, and systematic studies addressing the incidence, biology and clinical behavior of this form of MCL seem to be justified.
Journal ArticleDOI
Der Zeitfaktor in der Onkologie: Spielt die Gesamtbehandlungszeit in der Chemotherapie eine Rolle?
TL;DR: Tumor models with the resulting hypotheses and well-designed clinical trials will lead to progress in the treatment of malignant tumors.
Journal ArticleDOI
Growing evidence for an underestimation of poor-risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes
Christian Steidl,Julie Schanz,Michael Pfeilstöcker,Thomas Nösslinger,Barbara Hildebrandt,Andrea Kuendgen,Michael Lübbert,Regina Kunzmann,Aristoteles Giagounidis,Carlo Aul,Lorenz Trümper,Otto Krieger,Reinhard Stauder,Thomas Müller,Friedrich Wimazal,Peter Valent,Christa Fonatsch,Ulrich Germing,Detlef Haase +18 more
TL;DR: Clinical outcome of cytogenetic and blast count subgroups in a large cohort of 1440 patients with MDS suggests an equal prognostic significance of poor-risk cytogenetics compared with highly elevated BM blasts and suggests a higher score for unfavorable karyotypes in future integrative prognostic systems in MDS.
Journal ArticleDOI
ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome.
Tobias Overbeck,Johanna Arnemann,R. Waldmann-Beushausen,Lorenz Trümper,Friedrich A. Schöndube,Kirsten Reuter-Jessen,Bernhard C. Danner +6 more
TL;DR: High-level PI of ABCA3 in NSCLC showed poor disease-free and overall survival in this patient cohort, potentially indicating the relevance of ABC a3 in lung cancer.
Journal ArticleDOI
CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)
Norbert Schmitz,Samira Zeynalova,Bertram Glass,Ulrich Kaiser,Eva Cavallin-Ståhl,Max Wolf,Mathias Haenel,Markus Loeffler,Lorenz Trümper,Michael Pfreundschuh +9 more
TL;DR: Pts with aggressive lymphoma and aaIPI 0 or 1 show low frequencies of CNS relapse or progression, and there was no indication that the addition of etoposide to CHOP (CHOEP) reduced the risk of CNS disease in any patient cohort treated with chemotherapy and R.